Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Analysis of Long-term (Investment) Activity Ratios

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Celgene Corp., long-term (investment) activity ratios

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net fixed asset turnover
Total asset turnover
Equity turnover

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).


Net Fixed Asset Turnover
The net fixed asset turnover ratio exhibits relative stability throughout the period, fluctuating within a narrow range. It starts at 11.77 in 2014, slightly declines to 11.25 in 2015, then rises to peak at 12.12 in 2017 before decreasing again to 11.17 in 2018. This indicates a consistent capacity to generate sales from net fixed assets, with minor variations suggesting stable asset utilization efficiency over the years.
Total Asset Turnover
The total asset turnover ratio shows a noticeable decline from 0.44 in 2014 to 0.34 in 2015, followed by a recovery trend, increasing to 0.4 in 2016 and further improving to 0.43 in 2017 and 2018. This pattern implies an initial decrease in overall asset efficiency, possibly due to asset growth outpacing sales, with a subsequent restoration of efficiency as sales growth realigned with asset levels by 2017. The ratio remains constant between 2017 and 2018, indicating a stabilization in asset utilization.
Equity Turnover
The equity turnover ratio demonstrates a strong and consistent upward trend, rising significantly from 1.16 in 2014 to 2.48 in 2018. Each year shows a progressive increase, reflecting enhanced efficiency in generating revenue from shareholders' equity. This suggests effective management of equity capital to drive sales growth, with the ratio more than doubling over five years, indicating improving financial leverage or operational performance related to equity usage.

Net Fixed Asset Turnover

Celgene Corp., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Net product sales
Property, plant and equipment, net
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Net fixed asset turnover = Net product sales ÷ Property, plant and equipment, net
= ÷ =

2 Click competitor name to see calculations.


Net Product Sales
There is a consistent upward trend in net product sales over the five-year period. Sales increased from 7,564 million US dollars in 2014 to 15,265 million US dollars in 2018, more than doubling within this timeframe. The growth appears steady year-on-year, suggesting effective sales expansion or increased market demand.
Property, Plant and Equipment, Net
The net value of property, plant, and equipment also shows a steady increase, rising from 643 million US dollars in 2014 to 1,367 million US dollars in 2018. This upward trend indicates ongoing investment in fixed assets, which could be related to expansion or modernization efforts.
Net Fixed Asset Turnover
The net fixed asset turnover ratio remains relatively stable throughout the period, fluctuating slightly between 11.17 and 12.12. Despite the increase in fixed assets, the ratio suggests that asset utilization efficiency has been maintained without significant improvement or deterioration. The slight decrease to 11.17 by 2018 might indicate a minor decline in the efficiency of generating sales from fixed assets, although the change is not substantial.

Total Asset Turnover

Celgene Corp., total asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Net product sales
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Total asset turnover = Net product sales ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


Net Product Sales
Net product sales demonstrate a consistent upward trend over the five-year period. Starting at $7,564 million in 2014, sales increased steadily each year, reaching $15,265 million by the end of 2018. This represents a more than doubling in sales volume, indicating strong revenue growth and effective market penetration or product demand expansion.
Total Assets
Total assets show significant growth over the same period. Beginning at $17,340 million in 2014, the asset base expanded substantially to $35,480 million by 2018. The most notable increase occurred between 2014 and 2015, where total assets surged by over 50%. Afterward, asset growth continued but at a more moderate pace, suggesting ongoing investment or acquisitions contributing to the company's expansion.
Total Asset Turnover
Total asset turnover, which measures the efficiency of using assets to generate sales, started at 0.44 in 2014 and dropped to 0.34 in 2015. Following this decline, the ratio improved in subsequent years, reaching 0.43 in both 2017 and 2018, approaching the initial level. This pattern indicates an initial decrease in asset utilization efficiency, possibly due to rapid asset growth outpacing sales temporarily, followed by improved operational effectiveness as sales growth caught up with asset size.
Overall Observations
The data reveals a company in a growth phase, successfully increasing net product sales alongside a growing asset base. Asset investments appear to have been significant, particularly early in the period, with operational efficiency measured by asset turnover recovering after an initial dip. The stable and improving turnover ratios in the latter years imply enhanced management of assets to support sales growth, reflecting positively on operational efficiency and strategic resource allocation.

Equity Turnover

Celgene Corp., equity turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Net product sales
Stockholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Equity turnover = Net product sales ÷ Stockholders’ equity
= ÷ =

2 Click competitor name to see calculations.


Net Product Sales
Net product sales demonstrated a consistent upward trend over the five-year period, increasing each year from US$7,564 million at the end of 2014 to US$15,265 million by the end of 2018. This represents a significant growth, more than doubling the sales amount within the timeframe, indicating strong revenue enhancement and market demand expansion.
Stockholders’ Equity
Stockholders’ equity exhibited fluctuations during the same period. Starting at US$6,525 million in 2014, equity decreased in 2015 to US$5,919 million, then increased to US$6,599 million in 2016 and US$6,921 million in 2017, before declining again to US$6,161 million in 2018. This pattern suggests some volatility in equity levels, potentially reflecting dividend payments, share repurchases, or other equity-related activities impacting the capital base.
Equity Turnover
The equity turnover ratio showed a steady and notable increase, rising from 1.16 in 2014 to 2.48 in 2018. This increase highlights an improved efficiency in using equity to generate sales over time. The increment suggests that despite some fluctuations in equity, the company managed to generate greater levels of revenue per unit of equity, indicating enhancements in operational performance or asset utilization.